SuperworthKyntra Bio PE ratio KYNB
Share price divided by earnings per share over the last twelve months, since 2014.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 102×
- Feb 2020
- Earnings per share, 12 months
- $45.30
- to Jun 30, 2026
- Share price
- $4.58
- Oct 23, 2026
- Peer median
- 10.1×
Kyntra Bio's PE ratio is not a meaningful number today: a PE under 2 means one year's earnings came to half of what the whole company is worth or more, which takes a one-off gain (a sale, debt written off, a tax benefit) or EPS on another share basis.
It was last meaningful in Feb 2020, at 102×.
It earned $45.30 a share over the twelve months to Jun 30, 2026, against a share price of $4.58 on Oct 23, 2026. It has had no meaningful PE for most of its history, so the chart below shows the earnings per share a PE divides the price by.
Earnings per share over time
A PE divides the share price by these earnings. While they were a loss or a sliver, the PE meant nothing, so this chart shows the earnings themselves.
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $45.37 | n/a |
| FY2024 | −$11.93 | n/a |
| FY2023 | −$73.25 | n/a |
| FY2022 | −$78.50 | n/a |
| FY2021 | −$78.50 | n/a |
| FY2020 | −$53.25 | n/a |
| FY2019 | −$24.00 | n/a |
| FY2018 | −$25.75 | n/a |
| FY2017 | −$41.75 | n/a |
| FY2016 | −$25.50 | n/a |
| FY2015 | −$38.00 | n/a |
| FY2014 | −$125.75 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $2.96 | n/a | $45.30 | |
| Q1 FY26 | −$3.76 | −427% | $40.46 | |
| Q4 FY25 | −$3.51 | −179% | $45.37 | |
| Q3 FY25 | $49.61 | n/a | $53.34 | |
| Q2 FY25 | −$1.88 | n/a | −$0.52 | |
| Q1 FY25 | $1.15 | n/a | −$2.53 | |
| Q4 FY24 | $4.46 | n/a | −$11.93 | |
| Q3 FY24 | −$4.25 | n/a | −$30.64 | |
| Q2 FY24 | −$3.89 | n/a | −$42.64 | |
| Q1 FY24 | −$8.25 | n/a | −$61.25 | |
| Q4 FY23 | −$14.25 | n/a | −$73.25 | |
| Q3 FY23 | −$16.25 | n/a | −$76.50 |
Against its peers
Companies in Drug Manufacturers - General nearest Kyntra Bio's size, closest first, today.
| Company | PE ratio |
|---|---|
| KYNBKyntra Bio | n/m |
| ATNMActinium Pharmaceuticals | 4.2× |
| SPROSpero Therapeutics | 10.1× |
| LFVNLifevantage | 14.7× |
| Peer median | 10.1× |
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on Kyntra Bio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.